CN1049430C - 磺酰胺类化合物、其制备方法及其应用 - Google Patents

磺酰胺类化合物、其制备方法及其应用 Download PDF

Info

Publication number
CN1049430C
CN1049430C CN93120171A CN93120171A CN1049430C CN 1049430 C CN1049430 C CN 1049430C CN 93120171 A CN93120171 A CN 93120171A CN 93120171 A CN93120171 A CN 93120171A CN 1049430 C CN1049430 C CN 1049430C
Authority
CN
China
Prior art keywords
chloro
pyrimidine
methoxyl group
benzsulfamide
tertiary butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN93120171A
Other languages
English (en)
Chinese (zh)
Other versions
CN1095375A (zh
Inventor
V·布卢
K·布力
Ｊ·－Ｍ·卡萨尔
M·克罗策尔
G·赫思
Ｂ·－Ｍ·勒弗勒
M·米勒
W·乃哈特
H·拉木兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1095375A publication Critical patent/CN1095375A/zh
Application granted granted Critical
Publication of CN1049430C publication Critical patent/CN1049430C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heat Treatment Of Articles (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Bipolar Transistors (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
CN93120171A 1992-12-10 1993-12-09 磺酰胺类化合物、其制备方法及其应用 Expired - Fee Related CN1049430C (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CH3777/1992 1992-12-10
CH3777/92 1992-12-10
CH377792 1992-12-10
CH379992 1992-12-11
CH3799/1992 1992-12-11
CH3799/92 1992-12-11
CH311493 1993-10-14
CH3114/93 1993-10-14
CH3114/1993 1993-10-14

Publications (2)

Publication Number Publication Date
CN1095375A CN1095375A (zh) 1994-11-23
CN1049430C true CN1049430C (zh) 2000-02-16

Family

ID=27174140

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93120171A Expired - Fee Related CN1049430C (zh) 1992-12-10 1993-12-09 磺酰胺类化合物、其制备方法及其应用

Country Status (19)

Country Link
US (1) US5420129A (enExample)
EP (1) EP0601386B1 (enExample)
JP (1) JPH0826006B2 (enExample)
KR (1) KR100300503B1 (enExample)
CN (1) CN1049430C (enExample)
AT (1) ATE232204T1 (enExample)
AU (1) AU669019B2 (enExample)
CA (1) CA2110944A1 (enExample)
CZ (1) CZ288030B6 (enExample)
DE (1) DE59310329D1 (enExample)
DK (1) DK0601386T3 (enExample)
ES (1) ES2190430T3 (enExample)
FI (1) FI112217B (enExample)
HU (1) HUT65689A (enExample)
IL (1) IL107884A (enExample)
NO (1) NO306344B1 (enExample)
NZ (1) NZ250347A (enExample)
PH (1) PH30118A (enExample)
TW (1) TW287160B (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5767310A (en) * 1993-03-19 1998-06-16 Merck & Co., Inc. Phenoxyphenylacetic acid derivatives
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
IL111959A (en) * 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) * 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
CA2162630C (en) * 1994-11-25 2007-05-01 Volker Breu Sulfonamides
EP0799206B1 (en) * 1994-12-20 2002-09-11 F. Hoffmann-La Roche Ag Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists
RU2151767C1 (ru) * 1994-12-20 2000-06-27 Ф.Хоффманн-Ля Рош Аг Сульфонамиды и фармацевтическая композиция
TW313568B (enExample) * 1994-12-20 1997-08-21 Hoffmann La Roche
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5573762A (en) * 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) * 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
CN1105711C (zh) * 1995-09-06 2003-04-16 兴和株式会社 嘧啶衍生物
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
CZ260596A3 (en) * 1995-10-12 1997-12-17 Hoffmann La Roche Sulfonamide derivative, process of its preparation and pharmaceutical composition containing thereof
ATE201202T1 (de) * 1995-12-20 2001-06-15 Yamanouchi Pharma Co Ltd Arylethensulfonamid-derivate und diese enthaltende medikamente
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
CZ263098A3 (cs) 1996-02-20 1999-05-12 Bristol-Myers Squibb Company Způsoby přípravy bifenylisoxazolsulfonamidů
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5958905A (en) * 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
ZA978334B (en) * 1996-09-16 1999-03-16 Univ Dalhousie Use of IFG-I for the treatment of kidney disorders renal insufficiencies steriod toxicity and related indications
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
ID25921A (id) 1997-04-28 2000-11-09 Texas Biotechnology Corp Sulfonamida-sulfonamida untuk pengobatan penyakit-penyakit yang dimediakan endotelin
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
HUP0201320A2 (en) 1999-03-19 2002-08-28 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamides and intermediates thereof
ES2255973T3 (es) * 2000-01-25 2006-07-16 F. Hoffmann-La Roche Ag Preparacion de sulfonamidas.
AU2001263850A1 (en) * 2000-04-20 2001-11-07 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity
AU2001265871A1 (en) * 2000-04-25 2001-11-07 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
MY140724A (en) * 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
CA2463976C (en) 2001-10-26 2007-02-13 Benedetta Crescenzi N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
DK1441734T3 (da) 2001-10-26 2007-06-11 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carboxamid-inhibitorer a HIV-integrase
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
NZ566263A (en) * 2002-05-24 2009-09-25 Millennium Pharm Inc CCR9 inhibitors and methods of use thereof
CN103169708B (zh) 2002-07-29 2018-02-02 里格尔药品股份有限公司 用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
DE102004027119A1 (de) 2003-06-06 2004-12-30 Schott Ag UV-Strahlung absorbierendes Glas mit geringer Absorption im sichtbaren Bereich, ein Verfahren zu seiner Herstellung sowie dessen Verwendung
US7122542B2 (en) * 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
KR100847203B1 (ko) * 2004-06-28 2008-07-17 에프. 호프만-라 로슈 아게 피리미딘 유도체
RU2375351C2 (ru) 2004-06-28 2009-12-10 Ф.Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩИМ ДЕЙСТВИЕМ В ОТНОШЕНИИ 11b-HSD1
ATE540035T1 (de) * 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US20060270694A1 (en) * 2005-05-03 2006-11-30 Rigel Pharmaceuticals, Inc. JAK kinase inhibitors and their uses
RU2008136317A (ru) * 2006-03-13 2010-04-20 Инсайсив Фармасьютикалз, Инк. (US) Способы и композиции для лечения диагностикой сердечной недостаточности
KR20080102200A (ko) * 2006-03-13 2008-11-24 엔싸이시브 파마슈티칼즈 인코퍼레이티드 시탁센탄 나트륨의 제제
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
WO2009095933A2 (en) * 2008-01-10 2009-08-06 Msn Laboratories Limited Improved and novel process for the preparation of bosentan
TWI555746B (zh) * 2009-12-28 2016-11-01 財團法人生物技術開發中心 作為ｍＴＯＲ及ＰＩ３Ｋ抑制劑之新穎嘧啶化合物
US9315491B2 (en) 2009-12-28 2016-04-19 Development Center For Biotechnology Pyrimidine compounds as mTOR and PI3K inhibitors
EP3981406A1 (en) * 2014-07-03 2022-04-13 Afferent Pharmaceuticals Inc. Methods and compositions for treating diseases and conditions
EP4149929A1 (en) 2020-05-12 2023-03-22 Bayer Aktiengesellschaft Triazine and pyrimidine (thio)amides as fungicidal compounds
BR112022024394A2 (pt) 2020-06-04 2023-01-31 Bayer Ag Heterociclil pirimidinas e triazinas como novos fungicidas
TWI833430B (zh) * 2021-11-08 2024-02-21 大陸商正大天晴藥業集團股份有限公司 氮雜聯苯類化合物及其應用
CN118667088A (zh) * 2024-05-30 2024-09-20 中国人民解放军北部战区总医院 二茂铁基硫代二氢嘧啶酮结构的聚合物及制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0510526A1 (de) * 1991-04-25 1992-10-28 F.Hoffmann-La Roche & Co. Aktiengesellschaft Verwendung von Sulfonamiden als Heilmittel und neue Sulfonamide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0510526A1 (de) * 1991-04-25 1992-10-28 F.Hoffmann-La Roche & Co. Aktiengesellschaft Verwendung von Sulfonamiden als Heilmittel und neue Sulfonamide

Also Published As

Publication number Publication date
DK0601386T3 (da) 2003-05-26
NO934502D0 (no) 1993-12-09
EP0601386A1 (de) 1994-06-15
CZ288030B6 (cs) 2001-04-11
AU669019B2 (en) 1996-05-23
KR100300503B1 (ko) 2001-11-22
NO306344B1 (no) 1999-10-25
KR940014347A (ko) 1994-07-18
DE59310329D1 (de) 2003-03-13
TW287160B (enExample) 1996-10-01
US5420129A (en) 1995-05-30
IL107884A0 (en) 1994-04-12
FI112217B (fi) 2003-11-14
FI935555L (fi) 1994-06-11
HUT65689A (en) 1994-07-28
CZ268493A3 (en) 1994-06-15
JPH06211810A (ja) 1994-08-02
ATE232204T1 (de) 2003-02-15
FI935555A0 (fi) 1993-12-10
AU5218993A (en) 1994-06-23
CA2110944A1 (en) 1994-06-11
IL107884A (en) 1998-03-10
PH30118A (en) 1996-12-27
ES2190430T3 (es) 2003-08-01
NO934502L (no) 1994-06-13
EP0601386B1 (de) 2003-02-05
HU9303458D0 (en) 1994-04-28
CN1095375A (zh) 1994-11-23
JPH0826006B2 (ja) 1996-03-13
NZ250347A (en) 1995-12-21

Similar Documents

Publication Publication Date Title
CN1049430C (zh) 磺酰胺类化合物、其制备方法及其应用
CN1035253C (zh) 吡喃基氰基胍衍生物的制备方法
CN1129597C (zh) 杂环化合物和以其为有效成分的抗肿瘤剂
CN1050839C (zh) 磺酰氨基嘧啶类化合物，含有它们的药物组合物及其制备方法与用途
CN1171885C (zh) 苯并咪唑衍生物晶体及其制备
CN100339080C (zh) 抗病毒大环化合物
CN1646519A (zh) N－苯基－2－嘧啶－胺衍生物的n－氧化物
CN1045776C (zh) 吡啶环取代的噻唑烷和噁唑烷以及它们作为降血糖药的用途
CN1170827C (zh) 苯并呋喃基吡喃酮衍生物
CN1872850A (zh) N－苯基－2－嘧啶胺衍生物
CN1060172C (zh) 取代的联苯磺酰胺类内皮素拮抗剂
CN1440403A (zh) 喹唑啉二甲苯磺酸盐化合物
CN1190424C (zh) 含喹啉的α－酮酰胺半胱氨酸和丝氨酸蛋白酶抑制剂
CN1516691A (zh) 苯基吡啶甲酰哌嗪衍生物
CN1561340A (zh) 新的1,2,4－三唑类化合物
CN1639187A (zh) 有效抗c型肝炎病毒的大环肽
CN1296488A (zh) 双环异羟肟酸类衍生物
CN1524079A (zh) 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用
CN1192739A (zh) N－杂芳基吡啶磺酰胺衍生物及其作为内皮素拮抗剂的用途
CN1694708A (zh) TGFβ的抑制剂
CN1144802A (zh) 哒嗪酮衍生物及其制备方法
CN1070488C (zh) 杀灭螺旋杆菌用的取代芳烷基硫代烷基硫代吡啶
CN1305472A (zh) 新的2,5－吡啶二羧酸衍生物
CN1662510A (zh) 5－(1,3－噁唑－2－基)苯甲酸衍生物的制备方法
CN1061350C (zh) 2,7－取代的八氢－吡咯并[1,2－a]吡嗪衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee